# Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients

> **NCT03874000** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** Metformin Hydrochloride

## Key facts

- **NCT ID:** NCT03874000
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-08
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-06-05
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874000, "Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03874000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*